 Myeloid-Lymphoid Leukemia Protein
"Myeloid-Lymphoid Leukemia Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
| Descriptor ID |
D051788
|
| MeSH Number(s) |
D12.776.260.560 D12.776.624.664.700.148 D12.776.930.483
|
| Concept/Terms |
Myeloid-Lymphoid Leukemia Protein- Myeloid-Lymphoid Leukemia Protein
- Myeloid Lymphoid Leukemia Protein
- Zinc Finger Protein HRX
- MLL Proto-Oncogene Protein
- MLL Proto Oncogene Protein
- Proto-Oncogene Protein, MLL
- Proto-Oncogene Proteins MLL
- MLL, Proto-Oncogene Proteins
- Proto Oncogene Proteins MLL
- Acute Lymphoblastic Leukemia Protein 1
- Mixed-Lineage Leukemia Protein
- Mixed Lineage Leukemia Protein
|
Below are MeSH descriptors whose meaning is more general than "Myeloid-Lymphoid Leukemia Protein".
Below are MeSH descriptors whose meaning is more specific than "Myeloid-Lymphoid Leukemia Protein".
This graph shows the total number of publications written about "Myeloid-Lymphoid Leukemia Protein" by people in this website by year, and whether "Myeloid-Lymphoid Leukemia Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2009 | 4 | 0 | 4 | | 2010 | 3 | 1 | 4 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 0 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 8 | 0 | 8 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 0 | 3 | | 2020 | 2 | 0 | 2 | | 2021 | 4 | 2 | 6 | | 2022 | 1 | 0 | 1 | | 2024 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Myeloid-Lymphoid Leukemia Protein" by people in Profiles.
-
Guest EM, Kairalla JA, Devidas M, Hibbitts E, Carroll AJ, Heerema NA, Kubaney HR, August MA, Ramesh S, Yoo B, Farooqi MS, Pauly MG, Wechsler DS, Miles RR, Reid JM, Kihei CD, Gore L, Raetz EA, Hunger SP, Loh ML, Brown PA. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1. Haematologica. 2024 Dec 01; 109(12):3918-3927.
-
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan; 43(1):75-84.
-
Liu W, Cao H, Wang J, Elmusrati A, Han B, Chen W, Zhou P, Li X, Keysar S, Jimeno A, Wang CY. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma. Nat Commun. 2024 Aug 08; 15(1):6755.
-
Yokoyama A, Niida H, Kutateladze TG, C?t? J. HBO1, a MYSTerious KAT and its links to cancer. Biochim Biophys Acta Gene Regul Mech. 2024 09; 1867(3):195045.
-
Becht DC, Mohid SA, Lee JE, Zandian M, Benz C, Biswas S, Sinha VK, Ivarsson Y, Ge K, Zhang Y, Kutateladze TG. MLL4 binds TET3. Structure. 2024 Jun 06; 32(6):706-714.e3.
-
Murphy L, Siegele B, Carstens B, Hartman L, Faulk K. A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy. Leuk Lymphoma. 2024 Jun; 65(6):843-847.
-
Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022 05 01; 107(5):1205-1208.
-
Liao W, Kohler ME, Fry T, Ernst P. Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia. Exp Hematol. 2021 08; 100:1-11.
-
Jaiswal AK, Truong H, Tran TM, Lin TL, Casero D, Alberti MO, Rao DS. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Sci Rep. 2021 06 23; 11(1):13158.
-
Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 05 14; 12(1):2792.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|